Pfizer's COVID-19 Vaccine Generates $36 Billion in Revenue
New York-based Pfizer Inc. announced today the Comirnaty vaccine would generate approximately $36 billion in revenues for the company this year. Pfizer's previous mRNA COVID-19 vaccine revenue forecast was approximately $33.5 billion.
The Comirnaty vaccine revenue projection incorporated within Pfizer's 2021 financial guidance includes approximately 2.3 billion doses that are expected to be delivered in fiscal 2021, based on expected ordering patterns through the end of December 2021 for the U.S. market and through the end of November for the rest of the world.
Total company third-quarter 2021 revenues totaled $24.1 billion, an increase of $13.8 billion, or 134%, compared to the prior-year quarter.
In addition, Comirnaty contributed $13 billion in direct sales and alliance revenues.
Dr. Albert Bourla, Pfizer's Chairman and CEO, stated in a press release, "While we are proud of our third quarter financial performance, we are even more proud of what these financial results represent in terms of the positive impact we are having on human lives around the world."
"For example, more than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty have come from supplying countries outside the U.S."
"And we remain on track to achieve our goal of delivering at least two billion doses to low- and middle-income countries by the end of 2022 -- at least one billion to be delivered this year and one billion next year."
Comirnaty is the first COVID-19 vaccine Approved by the U.S. FDA and had previously been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020.
The vaccine remains available to individuals 12 to 15 years old under a EUA granted by the FDA on May 10, 2021.
In September 2021, Pfizer and BioNTech announced that the FDA authorized for emergency use a booster dose of Comirnaty for specific populations.
In October 2021, Pfizer and BioNTech announced that the FDA had authorized BNT162b2 for emergency use for children 5 through 11 years of age. The vaccine is to be administered in a two-dose regimen of 10 µg doses given 21 days apart for this group.
Separately, the US Centers for Disease Control and Prevention confirmed that its vaccine advisory committee would meet on November 2, 2021, to review Comirnaty vaccine information focused on children aged 5-11 years. The agenda for this Advisory Committee on Immunization Practices meeting has been released.
Our Trust Standards: Medical Advisory Committee